Table 1.

Baseline characteristics of cohort; these characteristics were retained in the prediction models. The“number of antihypertensive agents” variable was incorporated into the risk score for adults age 80+, but not into the risk score for adults ages 65-79.Values provided are percentages of total cohort. eGFR = estimated glomerular filtration rate. BMI = Body mass index.

Total cohort n= 4,054
Baseline characteristics	Ages 65-79 (n = 1,915)	Ages ≥80 (n = 2,139 )
Gender (% female)	27.4	34.9
eGFR (ml/min/1.73m2)
≤15	2.7	2.4
16-29	44.6	50.4
Coronary artery disease	19.4	22.0
Heart failure	18.3	24.7
Hypertension	38.0	40.7
Peripheral vascular disease	9.9	9.4
Diabetes	25.0	14.8
Stroke	5.4	6.0
* Tobacco abuse	10.5	4.9
Statin use	26.9	18.3
** Number of antihypertensive medications
0	2.5	3.8
1-2	1.8	1.8
3+	43.0	47.1
BMI (kg/m2)
≤18.5	0.5	1.4
18.6-30	22.8	32.3
>30	20.9	11.3
Non-disease specific measures***	(n=1688)	(n=1640)
Weight loss of≥10 lbs. during a 12 month period****	20.5	17.0
≥ 2 ER or Inpatient admissions in 2 years prior to cohort entry	29.2	31.2
Orthostatic hypotension	1.9	1.7
Hip fracture during the 2 years prior to cohort entry	0.8	1.7
Dementia diagnosis in the 3 months prior to cohort entry	0.8	1.6
Fall during the 2 years prior to cohort entry	1.8	3.4
Number of non-disease specific measures
Zero	15.6	12.4
1-2	32.6	33.0
≥3	2.5	3.9

^*Tobacco abuse refers to documentation of smoking history during the 2 year period prior to cohort entry.

^**Number of antihypertensive medications refers to the number of medications prescribed during the 3 months prior to index (0, 1-2, or 3+ medications)

^***Percent of patients with non-disease specific measures was based number of patients with two weight values during 2 year period prior to cohort entry, which was necessary for estimation of weight loss.

^****Two documented weights no more than 12 months apart during the 2-year baseline period prior to cohort entry were used to assess this characteristic.